

Andres Pineda, Fscai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7122227/publications.pdf>

Version: 2024-02-01

17
papers

322
citations

1163117

8
h-index

940533

16
g-index

17
all docs

17
docs citations

17
times ranked

526
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 139, 1661-1670. | 1.6 | 106 |
| 2 | Incidence, Temporal Trends, and Associated Outcomes of Vascular and Bleeding Complications in Patients Undergoing Transfemoral Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008227. | 3.9 | 49 |
| 3 | Trends in Usage and Clinical Outcomes of Coronary Atherectomy. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008239. | 3.9 | 36 |
| 4 | Clinical impact of baseline chronic kidney disease in patients undergoing transcatheter or surgical aortic valve replacement. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 740-748. | 1.7 | 27 |
| 5 | Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients Treated With Morphine. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1538-1549. | 2.9 | 26 |
| 6 | Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes. <i>JACC Basic To Translational Science</i> , 2020, 5, 419-428. | 4.1 | 18 |
| 7 | Racial and ethnic disparities in coronary, vascular, structural, and congenital heart disease. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 277-294. | 1.7 | 18 |
| 8 | Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus. <i>JACC Basic To Translational Science</i> , 2019, 4, 763-775. | 4.1 | 12 |
| 9 | Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Previous Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention. <i>Circulation</i> , 2020, 142, 1500-1502. | 1.6 | 10 |
| 10 | Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 728-737. | 3.0 | 6 |
| 11 | Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic Disease. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1341-1351. | 3.4 | 5 |
| 12 | Challenges for Expanded Use of Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, . | 3.9 | 3 |
| 13 | Oral Anticoagulation After TAVR in Patients With Atrial Fibrillation. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1577-1579. | 2.9 | 2 |
| 14 | Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 452-461. | 3.0 | 2 |
| 15 | Identifying opportunities to advance health equity in interventional cardiology: Structural heart disease. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 1165-1171. | 1.7 | 1 |
| 16 | Type A Aortic Dissection Following a Transcatheter Aortic Valve Replacement in a Prohibitive Surgical Risk Candidate. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, , . | 1.3 | 1 |
| 17 | Pharmacodynamic profiles of aspirin versus dual-pathway inhibition with either aspirin or clopidogrel among patients with stable atherosclerotic disease. <i>European Heart Journal Supplements</i> , 2021, 23, . | 0.1 | 0 |